Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allan T Luskin

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
The Journal of Allergy and Clinical Immunology. in Practice|August 14, 2017
Asthma Exacerbations and Triggers in Children in TENOR: Impact on Quality of LifeBradley E Chipps, Tmirah Haselkorn, Karin Rosén, et al.
Journal of Managed Care & Specialty Pharmacy|October 31, 2017
Patient Outcomes, Health Care Resource Use, and Costs Associated with High Versus Low HEDIS Asthma Medication RatioAllan T Luskin, Evgeniya N Antonova, Michael S Broder, et al.
Allergy and Asthma Proceedings|May 27, 2006
The economic burden associated with prior authorizations in an allergist officeDon A Bukstein, Greeta A Cherayil, Adam D Gepner, et al.
Clinicoeconomics and Outcomes Research : CEOR|November 9, 2016
Health care resource use and costs associated with possible side effects of high oral corticosteroid use in asthma: a claims-based analysisAllan T Luskin, Evgeniya N Antonova, Michael S Broder, et al.
The Journal of Allergy and Clinical Immunology|November 10, 2016
A randomized multicenter study evaluating Xolair persistence of response after long-term therapyDennis Ledford, William Busse, Benjamin Trzaskoma, et al.
The Journal of Allergy and Clinical Immunology. in Practice|May 26, 2018
Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World StudyThomas B Casale, Allan T Luskin, William Busse, et al.
Allergy and Asthma Proceedings|March 1, 2011
Is there a role for aerosol nasal sprays in the treatment of allergic rhinitis: a white paperAllan T Luskin, Michael S Blaiss, Judith R Farrar, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|October 22, 2017
Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPEROBradley E Chipps, Robert S Zeiger, Allan T Luskin, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|December 22, 2004
The utility of the Health Plan Employer Data and Information Set (HEDIS) asthma measure to predict asthma-related outcomesWilliam E Berger, Antonio P Legorreta, Michael S Blaiss, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
The Journal of Allergy and Clinical Immunology. in Practice|August 14, 2017
Asthma Exacerbations and Triggers in Children in TENOR: Impact on Quality of LifeBradley E Chipps, Tmirah Haselkorn, Karin Rosén, et al.
Journal of Managed Care & Specialty Pharmacy|October 31, 2017
Patient Outcomes, Health Care Resource Use, and Costs Associated with High Versus Low HEDIS Asthma Medication RatioAllan T Luskin, Evgeniya N Antonova, Michael S Broder, et al.
Allergy and Asthma Proceedings|May 27, 2006
The economic burden associated with prior authorizations in an allergist officeDon A Bukstein, Greeta A Cherayil, Adam D Gepner, et al.
Clinicoeconomics and Outcomes Research : CEOR|November 9, 2016
Health care resource use and costs associated with possible side effects of high oral corticosteroid use in asthma: a claims-based analysisAllan T Luskin, Evgeniya N Antonova, Michael S Broder, et al.
The Journal of Allergy and Clinical Immunology|November 10, 2016
A randomized multicenter study evaluating Xolair persistence of response after long-term therapyDennis Ledford, William Busse, Benjamin Trzaskoma, et al.
The Journal of Allergy and Clinical Immunology. in Practice|May 26, 2018
Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World StudyThomas B Casale, Allan T Luskin, William Busse, et al.
Allergy and Asthma Proceedings|March 1, 2011
Is there a role for aerosol nasal sprays in the treatment of allergic rhinitis: a white paperAllan T Luskin, Michael S Blaiss, Judith R Farrar, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|October 22, 2017
Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPEROBradley E Chipps, Robert S Zeiger, Allan T Luskin, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|December 22, 2004
The utility of the Health Plan Employer Data and Information Set (HEDIS) asthma measure to predict asthma-related outcomesWilliam E Berger, Antonio P Legorreta, Michael S Blaiss, et al.
Pageof 2